Search filters

Filters
Clear All

Phase

  • 10
  • 15
  • 17
  • 11
  • 19
  • 76
  • 36
  • 3
  • 2
  • 71
  • 74
  • 2

Found 76 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Durvalumab (MEDI4736) with Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma
18 years - 99 years
All genders
Phase 3
Interventional
Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of cisplatin or carboplatin and pemetrexed. T Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the …
18 years - 99 years
All genders
Phase 2
This study is being done to evaluate if participants with HER2-positive breast cancer who have no cancer remaining at surgery after 12 weeks of chemotherapy and two HER-targeting therapies eliminate further chemotherapy after surgery. Eligible subjects would be those with HER2-positive breast cancer.
 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
18 years - 99 years
All genders
Phase 2
Interventional
This trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as …
 Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na ve Metastatic Anal Cancer Patients
18 years - 99 years
All genders
Interventional
This trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor …
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
18 years - 39 years
All genders
Phase 3
Interventional
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
18 years - 99 years
All genders
Phase 2
This research study is being conducted to assess the safety and efficacy of IPH4102, an investigative medication (medication not approved by the Food and Drug Administration (FDA) for subjects diagnosed with Sézary Syndrome (SS) or Mycosis Fungoides (MF) over the age of 18. Participants will be asked to complete the …
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.